 |
 |
does not seem very new to me: http://chelseatherapeutics.com/pipeline/droxidopa/droxidopa.html they must be recycling Droxidopa Droxidopa is an orally active synthetic precursor of norepinephrine currently approved and marketed in Japan for the treatment of orthostatic hypotension. By replenishing depleted norepinephrine via endogenous enzymatic pathway, Droxidopa allows for re-uptake of norepinephrine into peripheral nervous system neurons – stimulating receptors for vasoconstrinction and providing physiological improvement in symptomatic neurogenic orthostatic hypotension patients. With over 15 years of proven safety and efficacy in its target indications, Droxidopa provides a unique opportunity to accelerate Chelsea's drug development activities, expand its product pipeline and help finance the establishment of a sales and marketing infrastructure prior to commercialization of the company’s other compounds including CH-1504. Originally approved in 1989 for the treatment of frozen gait or dizziness associated with Parkinson's Disease and for the treatment of orthostatic hypotension, syncope or dizziness associated with Shy-Drager syndrome and Familial Amyloidotic Polyneuropathy, DSP expanded marketing approval in 2000 to include treatment of vertigo, dizziness and weakness associated with orthostatic hypotension in hemodialysis patients. ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn